Preparation， characterization and tissue distribution of polyethylene glycol-modified Curcumin solid lipid nanoparticle inhalable micropowder

LI Nan; WANG Zi; HAO Di; KONG Lingyu; LI Xu

doi:10.6039/j.issn.1001-0408.2025.19.05

您当前的位置：

首页 >

文章列表页 >

Preparation， characterization and tissue distribution of polyethylene glycol-modified Curcumin solid lipid nanoparticle inhalable micropowder

更新时间：2025-10-11

- Preparation， characterization and tissue distribution of polyethylene glycol-modified Curcumin solid lipid nanoparticle inhalable micropowder
- ZHONGGUO YAOFANG Vol. 36, Issue 19, Pages: 2387-2392(2025)
- 作者机构：
  
  天津市医药科学研究所，天津　300020
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2025.19.05
  CLC： R943
- Received：01 July 2025，
  
  Revised：2025-08-07，
  
  Accepted：12 September 2025，
  
  Published：15 October 2025
- 稿件说明：
移动端阅览
李楠,王梓,郝迪,等.聚乙二醇修饰姜黄素固体脂质纳米粒吸入微粉的制备、表征及组织分布研究[J].中国药房,2025,36(19):2387-2392.

LI Nan,WANG Zi,HAO Di,et al.Preparation， characterization and tissue distribution of polyethylene glycol-modified Curcumin solid lipid nanoparticle inhalable micropowder[J].ZHONGGUO YAOFANG,2025,36(19):2387-2392.
李楠,王梓,郝迪,等.聚乙二醇修饰姜黄素固体脂质纳米粒吸入微粉的制备、表征及组织分布研究[J].中国药房,2025,36(19):2387-2392. DOI： 10.6039/j.issn.1001-0408.2025.19.05.

LI Nan,WANG Zi,HAO Di,et al.Preparation， characterization and tissue distribution of polyethylene glycol-modified Curcumin solid lipid nanoparticle inhalable micropowder[J].ZHONGGUO YAOFANG,2025,36(19):2387-2392. DOI： 10.6039/j.issn.1001-0408.2025.19.05.

摘要

目的

制备吸入用聚乙二醇（PEG）修饰的花形乳糖（FL）装载姜黄素（Cur）固体脂质纳米粒（SLN）吸入微粉（简称“PEG-Cur-FL”）。

方法

采用溶剂乳化扩散-低温固化法制备PEG-Cur-FL，并对其包封率和载药量、粉体学性质、空气动力学粒径、体外沉积性质和体外释放特性进行表征。将小鼠分为Cur-SLN-FL（未经PEG修饰）组和PEG-Cur-FL组，每组55只。两组小鼠均单次经气管吸入相应药物微粉5 mg/kg（以Cur计），分别于给药后0.25、0.5、1、2、4、6、8、12、24、48、72 h时摘眼球取血并分离其气管、肺、肝和肾组织，测定小鼠血浆和各组织样品中Cur的质量浓度，分析药物的组织分布和滞留情况。

结果

PEG-Cur-FL的包封率和载药量分别为（86.2±1.8）%和（4.2±0.2）%，松密度和振实密度分别为（0.24±0.01）g/cm

和（0.30±0.01）g/cm

，空气动力学粒径为（2.74±0.64）μm，体外有效部位沉积率（二级药物沉积率）为（45.07±2.79）%。与Cur原料药比较，Cur-SLN-FL和PEG-Cur-FL在漏槽和非漏槽条件下均具有缓释作用，且PEG-Cur-FL在人工肺液中的释放更平缓，释药特征符合Weibull模型。体内分布结果显示，PEG-Cur-FL组小鼠给药后1 h的肺组织药物浓度显著低于同期Cur-SLN-FL组，而4～48 h各时间点的肺组织药物浓度均显著高于同期Cur-SLN-FL组（

＜0.05）；PEG-Cur-FL组0.25～12 h各时间点的血浆药物浓度均显著低于同期Cur-SLN-FL组，肝、肾组织药物浓度亦低于同期Cur-SLN-FL组（

＜0.05）。

结论

成功制备PEG-Cur-FL；该吸入微粉具有良好的可吸入性能和释放性能；经气管内给药后可提高Cur在肺组织的药物有效浓度，同时降低其血浆药物浓度和非靶器官的药物分布浓度。

Abstract

OBJECTIVE

To prepare polyethylene glycol （PEG）-modified flower lactose （FL） loaded Curcumin （Cur） solid lipid nanoparticle （SLN） inhalable micropowder （referred to as “PEG-Cur-FL”）.

METHODS

PEG-Cur-FL was prepared by the solvent emulsification diffusion low-temperature solidification method， and its encapsulation efficiency， drug loading capacity， powder properties， aerodynamic particle size，

in vitro

deposition properties， and

in vitro

release characteristics were characterized. The mice were divided into Cur-SLN-FL （unmodified with PEG） group and PEG-Cur-FL group， with 55 mice in each group. Both groups of mice were given a single inhalation of 5 mg/kg （calculated as Cur） of the corresponding drug micropowder through an air tube. At 0.25， 0.5， 1， 2， 4， 6， 8， 12， 24， 48 and 72 hours after administration， eyeballs were removed to collect blood and tracheal， lung， liver and kidney tissues were separated. The mass concentration of Cur in mouse plasma and various tissue samples was measured， and the tissue distribution and retention of the drug were analyzed.

RESULTS

The encapsulation efficiency and drug loading capacity of PEG-Cur-FL were （86.2±1.8）% and （4.2±0.2）%， respectively； the bulk density and tap density were （0.24±0.01） g/cm

and （0.30±0.01） g/cm

， respectively； the aerodynamic particle size was （2.74±0.64） μm； the

in vitro

effective site deposition rate （secondary drug deposition rate） was （45.07±2.79）%. Compared with Cur raw materials， Cur-SLN-FL and PEG-Cur-FL had sustained release effects under both leakage and non-leakage conditions， and PEG-Cur-FL had a smoother sustained release in artificial lung fluid， with release characteristics consistent with the Weibull model. The results of

in vivo

distribution showed that the drug concentration in the lung tissue of PEG-Cur-FL group was significantly lower than that of Cur-SLN-FL group during the same period after 1 hour of administration， while the drug

concentration in the lung tissue at 4 to 48 hours was significantly higher than that of Cur-SLN-FL group during the same period （

＜0.05）； the plasma drug concentrations of the PEG-Cur-FL group at all time points from 0.25 to 12 hours were significantly lower than those of the Cur-SLN-FL group during the same period （

＜0.05）， and the drug concentrations in liver and kidney tissues were also lower than those of the Cur-SLN-FL group during the same period （

＜0.05）.

CONCLUSIONS

PEG-Cur-FL is prepared successfully； the inhalable micropowder has good inhalability and release performance； after administration through the trachea， the effective concentration of Cur in lung tissue can be increased， while reducing its plasma drug concentration and drug distribution concentration in non-target organs.

关键词

Keywords

references

陈典，隆寰宇，李姝润，等 . 2024 年 GOLD 慢性阻塞性肺疾病诊断、治疗、管理及预防全球策略更新要点解读 [J ] . 中国全科医学， 2024 ， 27 （ 13 ）： 1533 - 1567 .

GUO X L ， YANG S Q ， ZHU H J ， et al . Involvement of M2 macrophages polarization in PM 2.5 -induced COPD by upregulating MMP12 via IL4/STAT6 pathway [J ] . Ecotoxicol Environ Saf ， 2024 ， 283 ： 116793 .

李楠，李旭，王梓，等 . 花形乳糖装载姜黄素固体脂质纳米粒吸入微粉对COPD模型小鼠肺部炎症的影响及机制 [J ] . 中国药房， 2023 ， 34 （ 14 ）： 1691 - 1696 .

张瑞，陈亚飞，李小丽，等 . 姜黄素对慢性阻塞性肺疾病大鼠的改善作用及机制 [J ] . 中国新药与临床杂志， 2022 ， 41 （ 8 ）： 495 - 501 .

汪新娌，董伟，徐希强，等 . 姜黄素对慢性炎症性疾病抗炎作用研究进展 [J ] . 中国新药杂志， 2023 ， 32 （ 10 ）： 1028 - 1036 .

ABUDUREXITI M ， XUE J ， LI X Z ， et al . Curcumin/TGF-β 1 siRNA loaded solid lipid nanoparticles alleviate cerebral injury after intracerebral hemorrhage by transnasal brain targeting [J ] . Colloids Surf B Biointerfaces ， 2024 ， 237 ： 113857 .

李楠，李旭，程鹏，等 . 纳米多孔花形乳糖装载姜黄素固体脂质纳米粒吸入微粉的制备及其体外抑凋亡作用研究 [J ] . 中国药房， 2023 ， 34 （ 2 ）： 150 - 155 .

CHERAGA N ， SUN N C ， HUANG X X ， et al . Optimized rapamycin-loaded PEGylated PLGA nanoparticles：preparation，characterization and pharmacokinetics study [J ] . J Drug Deliv Sci Technol ， 2021 ， 61 ： 102144 .

冯世权，于佳岐，董德峤，等 . 超滤离心-HPLC法测定鲁索替尼固体脂质纳米粒的包封率 [J ] . 药学前沿， 2024 ， 28 （ 4 ）： 585 - 592 .

LI N ， LI X ， CHENG P ， et al . Preparation of curcumin solid lipid nanoparticles loaded with flower-shaped lactose for lung inhalation and preliminary evaluation of cytotoxicity in vitro [J ] . Evid Based Complement Alternat Med ， 2021 ， 2021 ： 4828169 .

李楠，李旭，程鹏，等 . 纳米多孔花形乳糖装载姜黄素干粉吸入剂的制备及体外释药性能研究 [J ] . 中国药房， 2021 ， 32 （ 7 ）： 794 - 801 .

BUDNIMATH S H ， BHUVANESHWARI G ， GANIGER V M ， et al . Physical，reconstitution and phenolic properties of instant drink mix prepared with Moringa oleifera leaf，raw banana and whey protein concentrate [J ] . Meas Food ， 2023 ， 11 ： 100108 .

国家药典委员会 . 中华人民共和国药典：四部 [M ] . 2020年版 . 北京：中国医药科技出版社， 2020 ： 202-206，192-199，466-472 .

YUE X ， LIANG J H ， ZHOU Y ， et al . Elucidating mixing process effects on pulmonary delivery efficiency of dry powder inhalers：a dual-dimensional macroscopic and microscopic perspective [J ] . Int J Pharm ， 2025 ， 677 ： 125652 .

COSTA M P ， ABDU J O C ， et al . Exploring the potential of PLGA nanoparticles for enhancing pulmonary drug delivery [J ] . Mol Pharmaceutics ， 2025 ， 22 （ 7 ）： 3542 - 3562 .

ZHANG X ， RAJARAMAN P K ， LI F ， et al . Assessment of ventilation heterogeneity and particle deposition in asthmatics using combined SPECT/CT imaging and computational modeling approaches [J ] . Eur J Pharm Sci ， 2025 ， 209 ： 107093 .

SHUKLA S K ， SARODE A ， KANABAR D D ， et al . Bioinspired particle engineering for non-invasive inhaled drug delivery to the lungs [J ] . Mater Sci Eng C Mater Biol Appl ， 2021 ， 128 ： 112324 .

CONG Y J ， CHEN W Y ， WEI J X ， et al . The pulmonary pharmacokinetics and anti-inflammatory effects after intratracheal and intravenous administration of Chuankezhi injection [J ] . Biomed Pharmacother ， 2022 ， 156 ： 113892 .

DHEGE C T ， KUMAR P ， CHOONARA Y E . Pulmonary drug delivery devices and nanosystems as potential treatment strategies for acute respiratory distress syndrome （ARDS） [J ] . Int J Pharm ， 2024 ， 657 ： 124182 .

ZHANG C Q ， D’ANGELO D ， BUTTINI F ， et al . Long-acting inhaled medicines：present and future [J ] . Adv Drug Deliv Rev ， 2024 ， 204 ： 115146 .

PAUL P K ， NAKPHENG T ， PALIWAL H ， et al . Inhalable solid lipid nanoparticles of levofloxacin for potential tuberculosis treatment [J ] . Int J Pharm ， 2024 ， 660 ： 124309 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

欧前胡素在大鼠体内的药动学与组织分布研究

磺胺嘧啶铈乳膏经大鼠阴道和皮肤给药后体内铈离子分布研究

骆驼蓬生物碱壳聚糖纳米粒在小鼠体内的组织分布

Stability，in vitro Release and Tissue Distribution of Docetaxel-dihydroartemisinin Conjugated Prodrug Self- assembled Nanoparticles

Study on Tissue Distribution of Apigenin Nanosuspension in Mice

Related Author

张笑恺曹蔚谢艳华段林瑞王四旺

张令春李晓天曹凤秋

李淑萍马桂芝付计瑞李岩滕亮王长虹于富生

LI Yujie

LI Ning

WANG Rongrong

ZHANG Shuqiu

REN Guolian

Related Institution

No data

Address：8th Floor, Sihuan Building, No. 129 Daping Main Street, Yuzhong District, Chongqing, China Postal code：400042
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰